These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Involvement of muscarinic receptor mechanisms in antidepressant drug action. Witkin JM; Smith JL; Golani LK; Brooks EA; Martin AE Adv Pharmacol; 2020; 89():311-356. PubMed ID: 32616212 [TBL] [Abstract][Full Text] [Related]
4. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973 [TBL] [Abstract][Full Text] [Related]
5. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Lauterbach EC Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777 [TBL] [Abstract][Full Text] [Related]
6. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine. Wohleb ES; Gerhard D; Thomas A; Duman RS Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968 [TBL] [Abstract][Full Text] [Related]
7. A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. Zanos P; Nelson ME; Highland JN; Krimmel SR; Georgiou P; Gould TD; Thompson SM eNeuro; 2017; 4(1):. PubMed ID: 28275719 [TBL] [Abstract][Full Text] [Related]
8. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Hashimoto K Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725 [TBL] [Abstract][Full Text] [Related]
9. An update on NMDA antagonists in depression. Pochwat B; Nowak G; Szewczyk B Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587 [No Abstract] [Full Text] [Related]
10. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacological innovation in the treatment of depression. Witkin JM; Golani LK; Smith JL Expert Rev Clin Pharmacol; 2023 Apr; 16(4):349-362. PubMed ID: 37000975 [TBL] [Abstract][Full Text] [Related]
12. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM; J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764 [TBL] [Abstract][Full Text] [Related]
13. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Dos Santos RG; Hallak JE; Baker G; Dursun S J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877 [TBL] [Abstract][Full Text] [Related]
14. mGlu2/3 receptor as a novel target for rapid acting antidepressants. Chaki S Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210 [TBL] [Abstract][Full Text] [Related]
15. Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. Martin AE; Schober DA; Nikolayev A; Tolstikov VV; Anderson WH; Higgs RE; Kuo MS; Laksmanan A; Catlow JT; Li X; Felder CC; Witkin JM CNS Neurol Disord Drug Targets; 2017; 16(4):492-500. PubMed ID: 28294051 [TBL] [Abstract][Full Text] [Related]
16. The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. Pałucha-Poniewiera A Pharmacol Rep; 2018 Oct; 70(5):837-846. PubMed ID: 30086517 [TBL] [Abstract][Full Text] [Related]
17. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960 [TBL] [Abstract][Full Text] [Related]
18. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583 [TBL] [Abstract][Full Text] [Related]
19. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Widman AJ; McMahon LL Proc Natl Acad Sci U S A; 2018 Mar; 115(13):E3007-E3016. PubMed ID: 29531088 [TBL] [Abstract][Full Text] [Related]
20. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]